Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Chi-Med Starts Phase I Trial of Cancer Drug in Australia

publication date: Apr 12, 2016
Hutchison China MediTech has dosed its initial patient in a first-in-human Phase I clinical trial of HMPL-689. The trial is being conducted in Australia. HMPL-689 is a novel small molecule inhibitor of the B-cell receptor signaling pathway, intended to treat B-cell cancers and autoimmune diseases. With this latest test underway, Chi-Med now has 24 trials involving seven novel drug candidates in progress. More details....

Stock Symbol: (NSDQ/AIM: HCM)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital